Eli Lilly and Company (NYSE:LLY) Stock Price Down 2% – Here’s Why

Shares of Eli Lilly and Company (NYSE:LLY) were down 2% during trading on Thursday . The company traded as low as $1,070.15 and last traded at $1,086.2750. Approximately 3,127,542 shares were traded during mid-day trading, a decline of 8% from the average daily volume of 3,404,246 shares. The stock had previously closed at $1,108.09.

Key Stories Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Zepbound (weight‑loss drug) combined with Taltz showed improved psoriatic‑arthritis symptom relief plus weight loss in a late‑stage trial — a clinical win that supports cross‑indication upside for Lilly’s obesity/cardiometabolic franchise. Lilly’s Zepbound plus Taltz boosts arthritis relief, weight loss
• Positive Sentiment: Lilly agreed to acquire inflammation specialist Ventyx Biosciences for $1.2B to add oral NLRP3‑focused small molecules — a targeted M&A move to diversify beyond GLP‑1 drugs and bolster its inflammation pipeline. Lilly to buy Ventyx Biosciences in $1.2 billion deal
• Positive Sentiment: Analyst coverage and strategy notes remain broadly supportive: Citigroup and other outlets highlight meaningful upside tied to Lilly’s pipeline and new launches, keeping investor focus on long‑term growth beyond GLP‑1. Eli Lilly Stock (LLY) Has 50% Upside, Says Citigroup
• Neutral Sentiment: Lilly continues to form partnerships and pipeline deals (e.g., Nimbus, InduPro collaborations) and was highlighted by Clarivate as having key cardiometabolic launches to watch in 2026 — supportive but incremental to near‑term stock moves. Boston biotech Nimbus to partner with Eli Lilly
• Neutral Sentiment: Some analysts are cautious on the Ventyx deal given science and NLRP3 uncertainty; Stifel maintained a hold on VTYX citing limited near‑term upside which tempers the immediate bullish narrative. Hold Rating Maintained on Eli Lilly’s Acquisition of Ventyx
• Negative Sentiment: Legal scrutiny: a law firm announced an investigation into Ventyx’s board over whether the $14/share sale to Lilly provided fair value — a corporate‑governance headwind that could create noise around the deal. SHAREHOLDER NOTICE: Brodsky & Smith Investigation of Ventyx
• Negative Sentiment: Regulatory/legal risk: Indiana’s attorney general filed suit over insulin pricing earlier this week — ongoing litigation and pricing scrutiny in key product areas remain potential downside catalysts. Indiana attorney general sues Eli Lilly over insulin pricing
• Negative Sentiment: Macro/competitive caution: commentary warns that GLP‑1 competition (including oral GLP‑1s) and a shift from price to volume could pressure margins or growth assumptions, prompting some profit‑taking after recent all‑time highs. Warning: This Skyrocketing Stock Has a Hidden Risk

Wall Street Analysts Forecast Growth

Several research analysts have issued reports on the stock. Guggenheim restated a “buy” rating and set a $1,163.00 price target on shares of Eli Lilly and Company in a report on Wednesday, December 3rd. Truist Financial increased their target price on shares of Eli Lilly and Company from $1,038.00 to $1,182.00 and gave the company a “buy” rating in a report on Wednesday, November 19th. UBS Group began coverage on Eli Lilly and Company in a research note on Tuesday. They issued a “buy” rating and a $1,250.00 price objective for the company. Loop Capital set a $950.00 price objective on Eli Lilly and Company in a research note on Monday, November 10th. Finally, HSBC reiterated a “hold” rating and issued a $1,070.00 price objective on shares of Eli Lilly and Company in a research note on Wednesday, December 10th. Five investment analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and four have given a Hold rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Buy” and an average price target of $1,169.00.

Eli Lilly and Company Stock Down 2.0%

The company has a 50 day moving average price of $1,028.26 and a 200-day moving average price of $856.98. The company has a debt-to-equity ratio of 1.71, a current ratio of 1.55 and a quick ratio of 1.24. The stock has a market capitalization of $1.03 trillion, a PE ratio of 53.14, a PEG ratio of 0.77 and a beta of 0.35.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings data on Thursday, October 30th. The company reported $7.02 EPS for the quarter, beating the consensus estimate of $6.42 by $0.60. Eli Lilly and Company had a return on equity of 109.52% and a net margin of 30.99%.The business had revenue of $17.60 billion during the quarter, compared to analyst estimates of $16.09 billion. During the same quarter last year, the firm posted $1.18 earnings per share. The company’s revenue for the quarter was up 53.9% on a year-over-year basis. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. As a group, analysts forecast that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, March 10th. Stockholders of record on Friday, February 13th will be issued a dividend of $1.73 per share. The ex-dividend date of this dividend is Friday, February 13th. This is an increase from Eli Lilly and Company’s previous quarterly dividend of $1.50. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.6%. Eli Lilly and Company’s dividend payout ratio is currently 33.86%.

Institutional Trading of Eli Lilly and Company

Several large investors have recently modified their holdings of LLY. 10Elms LLP raised its stake in Eli Lilly and Company by 33.3% during the 3rd quarter. 10Elms LLP now owns 40 shares of the company’s stock worth $31,000 after acquiring an additional 10 shares during the period. Bridgewater Advisors Inc. raised its holdings in Eli Lilly and Company by 0.3% during the 3rd quarter. Bridgewater Advisors Inc. now owns 3,955 shares of the company’s stock valued at $3,018,000 after buying an additional 11 shares during the period. Manske Wealth Management lifted its stake in Eli Lilly and Company by 2.5% in the third quarter. Manske Wealth Management now owns 448 shares of the company’s stock worth $342,000 after purchasing an additional 11 shares during the last quarter. Guardian Partners Inc. increased its stake in Eli Lilly and Company by 0.3% in the third quarter. Guardian Partners Inc. now owns 4,000 shares of the company’s stock worth $3,302,000 after purchasing an additional 12 shares during the period. Finally, Strategic Investment Solutions Inc. IL lifted its holdings in Eli Lilly and Company by 1.6% during the 3rd quarter. Strategic Investment Solutions Inc. IL now owns 741 shares of the company’s stock valued at $565,000 after buying an additional 12 shares in the last quarter. Institutional investors own 82.53% of the company’s stock.

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.